Summer Updates - We’re live on Crowdcube!
Dear Micrima Community,
We’re excited to share some big news and important updates with you this summer. It’s a truly transformative time at Micrima, and we're inviting you to join us on this journey.
We’re Crowdfunding – Invest in Women’s Health
We’re thrilled to announce that Micrima is now live on Crowdcube!
This is your opportunity to own a share of our mission to reinvent breast cancer diagnostics with our non-ionising, comfortable breast tissue measurement technology.
Invest from as little as £10 and become part of a movement to bring better screening to all women, especially those with dense breasts. The investment window is only open for a few weeks, so don’t miss this chance to support us and get involved. We have over 100 investors supporting our mission, and we would love you to join us and benefit as we grow. Click the button below to explore our campaign on CrowdCube, including perks of investing. Click the button below to view our campaign and invest in Crowdcube.
Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
From Lab to Life: First Devices in Production
Behind the scenes, our lab has been a hive of activity. We’ve restructured our space to support the commercial production of our very first batch of Mi~Scan® devices. This is a major step forward in bringing our innovation to clinics and patients.
We’re moving steadily through the medical device regulatory process, and we’re now awaiting feedback from our notified body on the next stage of approval. This milestone brings us even closer to delivering Mi~Scan® and density data into the hands of those who need it.
Breast Density in the News
Breast density is once again in the spotlight, both in the media and across healthcare policy.
UK Breast Screening Update: The UK National Screening Committee (UK NSC) has opened a consultation on whether additional breast screening should be offered to women with dense breasts. A decision is expected following their public feedback period, which started on 18 July 2025. *
UK Research (BRAID Study): The BRAID study is exploring the effectiveness of abbreviated MRI, contrast-enhanced mammography (CEM), and automated breast ultrasound (ABUS) to improve detection in dense tissue. Early results have been published and found Abbreviated MRI and contrast-enhanced mammography detected three times as many invasive cancers compared with ABUS, with cancers being half the size.** The BBC has published some amazing articles on this research this year, reporting over 80 young women who were identified as high risk because of the study. One of these ladies, a mother of two, stated she ‘felt like one of the lucky few’ to be informed about her density and risk.***
Samantha Womack’s Story: Singer and actress Samantha Womack has shared her breast cancer story in partnership with GenesisCare UK, a specialised cancer treatment centre. Samantha is encouraging women to ask about their breast density and advocate for themselves if they think something isn’t right.
International Momentum (a reminder):
Europe: The European Society of Breast Imaging (EUSOBI) recommends informing women of their breast density and offering MRI screening to those with extremely dense tissue.
USA: From September 2024, the FDA requires mammogram reports to include breast density information and recommendations for further screening.
These developments reinforce the importance of Micrima’s mission and innovation. As regulators and researchers catch up, we’re already building the technology that meets this urgent, unmet need. With Mi~Score®, we’re helping to shape a future where breast screening is based on personal risk, not one-size-fits-all guidelines. From more frequent screening for women with dense breasts to targeted care for those at highest risk, personalised pathways are the future. But to make this a reality, we need fast, reliable tools. That’s where Mi~Scan® and Mi~Score® come in, closing the gap with accessible, individualised risk assessment from a younger age. It’s time healthcare worked for all women.
Thank you for your continued support. Whether you’re an investor, follower, or advocate for women’s health, you’re helping us move closer to a world where all women have access to early breast cancer detection.
Let’s build that future together.
Warm regards,
The Micrima Team
References and Further Reading
** https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00582-3/fulltext